[G20-21] Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42
Last updated 15.10.2020
Project no.:
G20-21
Commission:
Commission awarded on 10.09.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-42 | Brigatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |